

# ACURIAN CASE STUDY:

Predictable, reliable, and  
measurable results



## Acurian Delivers 22% of Randomized Patients for a Phase II Trial of Patients with Diabetic Foot Ulcers

In order to begin phase III trials, a sponsor needed to complete the phase II study of its intramuscular injection therapy for patients who had diabetic foot ulcers with and without peripheral arterial disease. The plan was to randomize 133 dosed patients over an enrollment period of 26 months. However, shortly after the program was launched, enrollment began to fall behind. Sites had exhausted their databases and had become disengaged.

### The sponsor needed the most reliable solution for closing the gap and hired Acurian six months after enrollment began.

Acurian centrally pre-screens every respondent to ensure that only the most qualified candidates are referred to sites. For this study, accurate pre-screening of respondents with diabetic foot ulcers presented unique challenges. We uncovered that patients could not easily self-identify ulcers, and often their wounds were not the necessary size. These hurdles initially produced referrals that the sites deemed ineligible.

### Acurian quickly addressed the issues by:

- Having our Site Strategy Consultants work with sites to conduct thorough feasibility analyses to help them understand why candidates were disqualifying.
- Tightening our pre-screener and adding images of diabetic foot ulcers to help patients identify their own ulcers more accurately.
- Providing a pre-screen checklist for site use.


- Engaging a company to conduct additional pre-screening on behalf of the sites to reduce their workload and frustrations.
- Concentrating additional media ads around a subset of sites that the sponsor considered to be high priority sites.

As a result of these steps, site morale improved and First Office Visits, as well as randomization conversion rates, increased dramatically.

### Acurian delivered 22% of all randomizations and dosed subjects.

Even with a significantly smaller footprint of sites to support than originally planned, Acurian accounted for 22% of all randomized and dosed patients.


### Contribution of Randomized and Dosed Patients



(continued on other side)

## With Acurian's contribution to total randomizations, enrollment was shortened by four months.

Timelines would have been accelerated even more if Acurian had been engaged earlier in the program.



## WHEN YOU CAN'T AFFORD A DELAY IN PATIENT ENROLLMENT

Acurian, Inc. is the leading full-service provider of global patient enrollment and retention solutions for the life sciences industry. For the past 20 years, our unique patient-first approach has provided sponsors with enrollment certainty by delivering the patients they need, when and where they need them.

www.acurian.com  
enrollment.certainty@acurian.com  
264920178

**United States**  
Horsham, Pennsylvania  
215.323.9000

**Europe**  
Cambridge, United Kingdom  
+44 1223 374799